
NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the acute treatment of migraine, with …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

